Author pages are created from data sourced from our academic publisher partnerships and public sources.
Share This Author
The effect of CYP3A5 and MDR1 (ABCB1) polymorphisms on cyclosporine and tacrolimus dose requirements and trough blood levels in stable renal transplant patients.
Investigation of the effect of CYP3A5 and MDR1 (ABCB1) polymorphisms on cyclosporine and tacrolimus dose requirements and trough blood concentrations in stable transplant patients found that CYP 3A5*1/*3 polymorphism explained up to 45% of the variability in dose requirement in relation to tacolimus use.
Opportunities to Optimize Tacrolimus Therapy in Solid Organ Transplantation: Report of the European Consensus Conference
The importance of obtaining multicenter prospective trials to assess the efficacy of alternative strategies to TAC trough concentrations is emphasized, and single time points, limited sampling strategies, and area under concentration-time curve have all been considered to determine the most appropriate sampling procedure that correlates with efficacy.
Twelve‐Month Evaluation of the Clinical Pharmacokinetics of Total and Free Mycophenolic Acid and Its Glucuronide Metabolites in Renal Allograft Recipients on Low Dose Tacrolimus in Combination with…
It is suggested that trough plasma concentration monitoring of MPA and its metabolites might not provide a useful clinical tool for guiding MMF dose adjustments to avoid drug‐related toxicity.
CYP3A5 and ABCB1 Polymorphisms and Tacrolimus Pharmacokinetics in Renal Transplant Candidates: Guidelines from an Experimental Study
- V. Haufroid, P. Wallemacq, +6 authors M. Mourad
- MedicineAmerican journal of transplantation : official…
- 1 November 2006
This study confirms the very significant effect of CYP3A5 polymorphism early after the first administration of tacrolimus (Tac) and provides a strong argument for a doubling of the loading dose in patients early identified a priori on the transplantation list as possessing at least one CYP 3A5*1 allele.
Correlation of mycophenolic acid pharmacokinetic parameters with side effects in kidney transplant patients treated with mycophenolate mofetil.
A pharmacokinetic/pharmacodynamic relationship between MPA and clinical events is demonstrated and it is suggested that dividing the MMF daily oral dose into more than two divided doses might prevent early MPA toxicity.
CYP3A5 and ABCB1 polymorphisms influence tacrolimus concentrations in peripheral blood mononuclear cells after renal transplantation.
The ABCB1 1199G>A, 3435C>T and 2677G>T/A SNPs, appeared to reduce the activity of P-glycoprotein towards Tac, increasing Tac PBMC concentrations, which might enhance immunosuppressive status and prevention or rejection.
Minimally Invasive Video-assisted Thyroidectomy: Multiinstitutional Experience
- P. Miccoli, R. Bellantone, M. Mourad, M. Walz, M. Raffaelli, P. Berti
- MedicineWorld Journal of Surgery
- 30 July 2002
Although the operating time appears longer than with conventional procedures, the learning curve demonstrates a sharp decrease with increasing experience and the introduction of new technologies, and should be considered a valid option in selected surgical centers.
Restoring the association of the T cell receptor with CD8 reverses anergy in human tumor-infiltrating lymphocytes.
These lymphocytes recovered effector functions and TCR-CD8 colocalization after ex vivo treatment with galectin disaccharide ligands, suggesting the separation of TCR and CD8 molecules could be one major mechanism of anergy in tumors and other chronic stimulation conditions.
Pharmacokinetic basis for the efficient and safe use of low-dose mycophenolate mofetil in combination with tacrolimus in kidney transplantation.
The relationship between plasma MPA concentrations and toxicity is demonstrated and high c(min), c(30), and c(60) values as well as AUC((0-12)) are associated with increased risk for side effects.
Sirolimus and Tacrolimus Trough Concentrations and Dose Requirements after Kidney Transplantation in Relation to CYP3A5 and MDR1 Polymorphisms and Steroids
Unlike tacrolimus, sirolimus adjusted trough concentrations and dose requirements seem not affected by CYP3A5 and MDR1 polymorphisms.